Influencing factors for extracting total polysaccharides and active adjuvant components from Poria cocos / 国际药学研究杂志

Objection To investigate the main influencing factors for extracting total polysaccharides and two active adjuvant components from Poria cocos. Methods Extracting temperature was designed between 20℃-100℃,ratio of material/water was 1/5-1/20 (W/V),extracting time was 1-6 h,extracting frequency was 1-3 times,material size was crude slices~50 mesh,and extracting mode was standing or stirring. The sugar content was determined by phenol-sulfuric acid method and the reletive molecular mass of polysac-charides was determined with gel filtration chromatography. Monosaccharide compositions were analyzed with PMP-derivation and cap-illary electrophoresis. Results ①The extracting temperature should be below 70℃;②The ratio of material/water was suitable be-tween 1/5-1/20;③The extracting time might be within 2 h;④The extracting frequency should be no more than two times;⑤The raw material should be crushed before extracting;⑥The stirring was favorable for extracting polysaccharides. Conclusion The re-sults indicate that the extracting temperature,extracting frequency and stirring mode are important for extracting polysaccharides,and the cushing of the raw materials is helpful to extract the active adjuvant component of polysaccharides from P. cocos in higher yield.

STUDY ON THE DIFFERENCES OF MAJOR PHARMACEUTICAL INGREDIENTS IN DIFFERENT PARTS AND PROCESSED MEDICINAL MATERIAL OF EPIMEDIUM BREVICORNU MAXIM IN TAIHANG MOUNTAIN.

The aim of this study is to evaluate the medicinal values of different parts of Epimedium brevicornu Maxim. and the effect of processing on major pharmaceutical ingredients in it. The contents of icariin and epimedin C in different parts and processed medicinal material of E. brevicornu in Taihang Mountain were determined with ultrasonic extraction and RP-HPLC. The results indicated that the contents of icariin and epimedin C, respectively 3.4524% and 0.5485%, in the leaf are higher than that in other parts. The contents of icariin and epimedin C, respectively 0.1942 % and 0.1342%, in the stem (include petiole) are the lowest. The contents of these ingredients in the root (include rhizome) are close to that in the leaf. The icariin and epimedin C in all parts of E. brevicornu reduced after processing. The content of icariin in the processed leaf is about 59.5% of that in unprocessed leaves. The effect of prossing on the content of icariin in the stem is unobvious. The content of epimedin C in the processed leaf is about 33.7% of that in unprocessed leaf. The content of epimedin C in the processed stem (include petiole) is about 36.9% of that in unprocessed stem. It is worth to exploit the stem and petiole of E. brevicornu because there are certain contents of pharmaceutical ingredients in them. The firepower should be paid attention to and the temperature should not be very high to avoid the damage on pharmaceutical ingredients in E. brevicornu when process it.

Este estudio pretende evaluar los valores medicinales de diferentes partes de la Epimedium brevicornu Maxim y el efecto de su procesamiento sobre sus principales componentes farmacéuticos. El contenido de icariina y epimedin C en diferentes partes y en material medicinal procesado de Epimedium brevicornu en la montaña de Taihang fue determinado mediante extracción ultrasónica y RP-HPLC. Los resultados indicaron que el contenido de icariina y epimedin C, respectivamente 3,4524% y 0,5485%, en la hoja son mayores que en otras partes. El contenido de icariina y epimedin C, respectivamente 0,1942% y 0,1342%, en el tallo (peciolo incluido) es más bajo. El contenido de estos componentes en la raíz (rizoma incluido) es similar al de la hoja. El contenido de icariina y epimedin C en todas las partes de E. brevicornu se vio reducido después del procesado. El contenido de icariina en la hoja procesada es aproximadamente el 59,5% del de la hoja sin procesar. El efecto del procesado sobre el contenido de icariina en el tallo no es evidente. El contenido de epimedin C en el tallo procesado es de aproximadamente el 33,7% del de la hoja sin procesar. El contenido de epimedin C en el tallo procesado (peciolo incluido) es de aproximadamente el 36,9% de aquel del tallo sin procesar. Vale la pena aprovechar el tallo y peciolo de la E. brevicornu porque hay cierto contenido de componentes farmacéuticos en ellos. Hay que controlar la potencia de fuego y la temperatura no debe ser muy alta para evitar dañar los componentes farmacéuticos de la E. brevicornu.

Study on the differences of major pharmaceutical ingredients in different parts and processed medicinal material of Epimedium Brevicornu Maxim in Taihang mountain / Estudio sobre las diferencias de ingredientes farmacéuticos mayor en diferentes partes y procesado medicinal material de epimedium brevicornu maxim en taihang montaña

The aim of this study is to evaluate the medicinal values of different parts of Epimedium brevicornu Maxim. and the effect of processing on major pharmaceutical ingredients in it. The contents of icariin and epimedin C in different parts and processed medicinal material of E. brevicornu in Taihang Mountain were determined with ultrasonic extraction and RP-HPLC. The results indicated that the contents of icariin and epimedin C, respectively 3.4524% and 0.5485%, in the leaf are higher than that in other parts. The contents of icariin and epimedin C, respectively 0.1942 % and 0.1342%, in the stem (include petiole) are the lowest. The contents of these ingredients in the root (include rhizome) are close to that in the leaf. The icariin and epimedin C in all parts of E. brevicornu reduced after processing. The content of icariin in the processed leaf is about 59.5% of that in unprocessed leaves. The effect of prossing on the content of icariin in the stem is unobvious. The content of epimedin C in the processed leaf is about 33.7% of that in unprocessed leaf. The content of epimedin C in the processed stem (include petiole) is about 36.9% of that in unprocessed stem. It is worth to exploit the stem and petiole of E. brevicornu because there are certain contents of pharmaceutical ingredients in them. The firepower should be paid attention to and the temperature should not be very high to avoid the damage on pharmaceutical ingredients in E. brevicornu when process it (AU)

Este estudio pretende evaluar los valores medicinales de diferentes partes de la Epimedium brevicornu Maxim y el efecto de su procesamiento sobre sus principales componentes farmacéuticos. El contenido de icariina y epimedin C en diferentes partes y en material medicinal procesado de Epimedium brevicornu en la montaña de Taihang fue determinado mediante extracción ultrasónica y RP-HPLC. Los resultados indicaron que el contenido de icariina y epimedin C, respectivamente 3,4524% y 0,5485%, en la hoja son mayores que en otras partes. El contenido de icariina y epimedin C, respectivamente 0,1942% y 0,1342%, en el tallo (peciolo incluido) es más bajo. El contenido de estos componentes en la raíz (rizoma incluido) es similar al de la hoja. El contenido de icariina y epimedin C en todas las partes de E. brevicornu se vio reducido después del procesado. El contenido de icariina en la hoja procesada es aproximadamente el 59,5% del de la hoja sin procesar. El efecto del procesado sobre el contenido de icariina en el tallo no es evidente. El contenido de epimedin C en el tallo procesado es de aproximadamente el 33,7% del de la hoja sin procesar. El contenido de epimedin C en el tallo procesado (peciolo incluido) es de aproximadamente el 36,9% de aquel del tallo sin procesar. Vale la pena aprovechar el tallo y peciolo de la E. brevicornu porque hay cierto contenido de componentes farmacéuticos en ellos. Hay que controlar la potencia de fuego y la temperatura no debe ser muy alta para evitar dañar los componentes farmacéuticos de la E. brevicornu (AU)

Effect of yanghe huayan decoction on precancerosis of breast cancer, protein and mRNA expression of ki67: an experimental research / 中国中西医结合杂志

<p><b>OBJECTIVE</b>To explore the effect of Yanghe Huayan Decoction (YHD, a representative recipe for warming yang mass dissipating) in inhibiting precancerosis of breast cancer (PBC) and on the protein and mRNA expression of ki67.</p><p><b>METHODS</b>The PBC rat model was established by dimethylbenzanthracene (DMBA), and 9 weeks later rats were randomly divided into the blank control group, the model group, the YHD group, the Sanjie Huatan Decoction group (SHD), the Pingxiao Tablet group (PT), and the tamoxifen group. Rats in the model group were administered with water by gastrogavage. Rats in the YHD group received YHD (deglued antler powder 12 g, prepared rhizome of rehmannia 9 g, cassia bark 6 g, white mustard seed 3 g, zedoary root 12 g, appendiculate cremastra pseudobulb 15 g, chekiang fritillary bulb 9 g, licorice root 6 g) at the daily dose of 7.2 g/kg by gastrogavage. Rats in the SHD group received SHD (oldenlandia diffusa 15 g, Scutellaria Barbata 15 g, Trichosanthes Kirilowii 15 g, pinellia 9 g) at the daily dose of 5.4 g/kg by gastrogavage. Rats in the PT group received PT at the daily dose of 144 mg/kg by gastrogavage. Those in the tamoxifen group received tamoxifen at the daily dose of 4 mg/kg by gastrogavage. Pathomorphological changes of the breast tissue were observed by HE staining. The positive rate and the gray value of ki67 expression were detected by immunohistochemical assay. And the expression of ki67 mRNA was detected by q-PCR.</p><p><b>RESULTS</b>Compared with the model group, the general hyperplasia and the occurrence rate of precancerous lesion were higher and the occurrence rate of invasive carcinoma was lower in each treatment group (P < 0.05). Except the SHD group, the intensity of ki67 grey value increased in each treatment group (P < 0.05, P < 0.01). Except the PT group, the positive rate of ki67 and mRNA expression of ki67 increased in the rest treatment groups (P < 0.05, P < 0.01). Compared with the YHD group, there was no statistical difference in the occurrence rate of infiltration or the occurrence rate of precancerous lesion (P > 0.05). The positive rate of ki67 expression and mRNA expression of ki67 increased in the PT group, showing statistical difference (P < 0.05).</p><p><b>CONCLUSIONS</b>YHD could partially inhibit and reverse canceration of breast cancer. It also could inhibit ki67 protein and mRNA expression. Its effect was similar to tamoxifen and superior to PT. So it was suitable for prevention and treatment of precancerous lesion of breast cancer.</p>